CCL20 is a potential therapeutic target associated with immune infiltration in breast cancer

Objectives CCL20 is a chemotactic factor that is involved in immune cell recruitment and cancer progression. However, the role of CCL20 in the prognosis of breast cancer remains unclear. This study analyzed correlations between CCL20 expression and immune infiltration, clinicopathological parameters, and prognosis in breast cancer patients. Methods Correlations between CCL20 expression and clinicopathological parameters, prognosis, and immune infiltration in breast cancer were determined using the TIMER, UALCAN, and PrognoScan databases. Furthermore, gene–gene and protein–protein interactions were determined using GeneMANIA and STING network construction, respectively. Results CCL20 expression was significantly upregulated in breast cancer and had significant associations with clinicopathological features, including race, sex, age, menopause status, cancer stage, cancer subclass, and nodal metastasis; moreover, patients with higher CCL20 expression exhibited poor prognosis. Meanwhile, CCL20 expression was significantly correlated with the infiltration of immune cells in breast cancer, including monocytes, neutrophils, tumor-associated macrophages, Th1 cells, regulatory T cells, and exhausted T cells. Moreover, the network of CCL20 expression showed the majority genes and proteins were associated with immune reactions. Conclusions CCL20 is a prognosis-related biomarker in breast cancer on the basis of its correlation with immune infiltration levels and has potential to also be a therapeutic target.

[1]  T. Meshel,et al.  Correction: Erlichman et al. Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes. Cancers 2022, 14, 1042 , 2022, Cancers.

[2]  D. Cescon,et al.  Current Treatment and Future Trends of Immunotherapy in Breast Cancer. , 2022, Current cancer drug targets.

[3]  Q. Lei,et al.  D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1 , 2022, Proceedings of the National Academy of Sciences.

[4]  T. Meshel,et al.  Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes , 2022, Cancers.

[5]  Yibin Kang,et al.  Pharmacological Disruption of the MTDH-SND1 Complex Enhances Tumor Antigen Presentation and Synergizes with Anti-PD-1 Therapy in Metastatic Breast Cancer , 2021, Nature Cancer.

[6]  Luis E Munoz,et al.  Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer , 2020, Human vaccines & immunotherapeutics.

[7]  Shasha Liu,et al.  Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling , 2019, Journal of Immunotherapy for Cancer.

[8]  Adrian Y. S. Lee,et al.  The CCR6-CCL20 axis in humoral immunity and T-B cell immunobiology. , 2019, Immunobiology.

[9]  Vanessa M. Hubbard-Lucey,et al.  Immunotherapy and targeted therapy combinations in metastatic breast cancer. , 2019, The Lancet. Oncology.

[10]  R. Yang,et al.  CCR6 defines a subset of activated memory T cells of Th17 potential in immune thrombocytopenia , 2018, Clinical and experimental immunology.

[11]  H. Sokol,et al.  Expression of CCR6 and CXCR6 by Gut-Derived CD4+/CD8α+ T-Regulatory Cells, Which Are Decreased in Blood Samples From Patients With Inflammatory Bowel Diseases. , 2018, Gastroenterology.

[12]  J. Damås,et al.  C-C Motif Ligand 20 (CCL20) and C-C Motif Chemokine Receptor 6 (CCR6) in Human Peripheral Blood Mononuclear Cells: Dysregulated in Ulcerative Colitis and a Potential Role for CCL20 in IL-1β Release , 2018, International journal of molecular sciences.

[13]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[14]  X. Bian,et al.  CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer , 2018, PLoS biology.

[15]  M. Uguccioni,et al.  Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis , 2018, Arthritis Research & Therapy.

[16]  Lestat R. Ali,et al.  Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs , 2018, Cancer Immunology Research.

[17]  A. Muscella,et al.  CCL20 promotes migration and invasiveness of human cancerous breast epithelial cells in primary culture , 2017, Molecular carcinogenesis.

[18]  Kwang-Kyun Park,et al.  Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis , 2017, Scientific Reports.

[19]  Weiping Zou,et al.  Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.

[20]  Zong-tang Sun,et al.  CCR6+ B lymphocytes responding to tumor cell-derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis. , 2017, American journal of cancer research.

[21]  A. Kunnumakkara,et al.  Recent development of targeted approaches for the treatment of breast cancer , 2017, Breast Cancer.

[22]  Jun Ma,et al.  Tumor-associated macrophage-derived CCL20 enhances the growth and metastasis of pancreatic cancer. , 2016, Acta biochimica et biophysica Sinica.

[23]  A. Muscella,et al.  Paracrine CCL20 loop induces epithelial‐mesenchymal transition in breast epithelial cells , 2016, Molecular carcinogenesis.

[24]  H. Qu,et al.  CCR6 overexpression predicted advanced biological behaviors and poor prognosis in patients with gastric cancer , 2016, Clinical and Translational Oncology.

[25]  Shailesh Singh,et al.  CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition , 2016, British Journal of Cancer.

[26]  S. Torp,et al.  Expression of CCL20 and Its Corresponding Receptor CCR6 Is Enhanced in Active Inflammatory Bowel Disease, and TLR3 Mediates CCL20 Expression in Colonic Epithelial Cells , 2015, PloS one.

[27]  J. Pollard,et al.  Therapeutic potential of chemokine signal inhibition for metastatic breast cancer , 2015, Pharmacological research.

[28]  S. McColl,et al.  The chemokine receptor CCR6 facilitates the onset of mammary neoplasia in the MMTV-PyMT mouse model via recruitment of tumor-promoting macrophages , 2015, Molecular Cancer.

[29]  N. Munshi,et al.  CCR6, the Sole Receptor for the Chemokine CCL20, Promotes Spontaneous Intestinal Tumorigenesis , 2014, PloS one.

[30]  M. De la Fuente,et al.  Chronic Inflammation and Cytokines in the Tumor Microenvironment , 2014, Journal of immunology research.

[31]  D. Byamba,et al.  Dermal clusters of mature dendritic cells and T cells are associated with the CCL20/CCR6 chemokine system in chronic psoriasis. , 2014, The Journal of investigative dermatology.

[32]  Adrian Y. S. Lee,et al.  CCR6 and CCL20: emerging players in the pathogenesis of rheumatoid arthritis , 2014, Immunology and cell biology.

[33]  A. Muscella,et al.  CCL20 induces migration and proliferation on breast epithelial cells , 2013, Journal of cellular physiology.

[34]  Qing Yang,et al.  High Expression of CCL20 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma after Curative Resection , 2012, Journal of Gastrointestinal Surgery.

[35]  Max S Wicha,et al.  Breast cancer stem cells, cytokine networks, and the tumor microenvironment. , 2011, The Journal of clinical investigation.

[36]  M. Kulesz-Martin,et al.  Regulation of the psoriatic chemokine CCL20 by E3 ligases Trim32 and Piasy in keratinocytes. , 2010, The Journal of investigative dermatology.

[37]  T. Hehlgans,et al.  Specific Binding and Chemotactic Activity of mBD4 and Its Functional Orthologue hBD2 to CCR6-expressing Cells* , 2010, The Journal of Biological Chemistry.

[38]  J. Van Damme,et al.  The CC chemokine CCL20 and its receptor CCR6. , 2003, Cytokine & growth factor reviews.

[39]  S. McColl,et al.  Genomic organization of the CC chemokine mip-3alpha/CCL20/larc/exodus/SCYA20, showing gene structure, splice variants, and chromosome localization. , 2001, Genomics.

[40]  P. Proost,et al.  Regulated Production and Molecular Diversity of Human Liver and Activation-Regulated Chemokine/Macrophage Inflammatory Protein-3α from Normal and Transformed Cells1 , 2000, The Journal of Immunology.

[41]  Osamu Yoshie,et al.  Molecular Cloning of a Novel Human CC Chemokine Liver and Activation-regulated Chemokine (LARC) Expressed in Liver , 1997, The Journal of Biological Chemistry.